Literature DB >> 24335842

Structure-based ensemble-QSAR model: a novel approach to the study of the EGFR tyrosine kinase and its inhibitors.

Xian-qiang Sun1, Lei Chen2, Yao-zong Li3, Wei-hua Li2, Gui-xia Liu2, Yao-quan Tu4, Yun Tang2.   

Abstract

AIM: To develop a novel 3D-QSAR approach for study of the epidermal growth factor receptor tyrosine kinase (EGFR TK) and its inhibitors.
METHODS: One hundred thirty nine EGFR TK inhibitors were classified into 3 clusters. Ensemble docking of these inhibitors with 19 EGFR TK crystal structures was performed. Three protein structures that showed the best recognition of each cluster were selected based on the docking results. Then, a novel QSAR (ensemble-QSAR) building method was developed based on the ligand conformations determined by the corresponding protein structures.
RESULTS: Compared with the 3D-QSAR model, in which the ligand conformations were determined by a single protein structure, ensemble-QSAR exhibited higher R2 (0.87) and Q2 (0.78) values and thus appeared to be a more reliable and better predictive model. Ensemble-QSAR was also able to more accurately describe the interactions between the target and the ligands.
CONCLUSION: The novel ensemble-QSAR model built in this study outperforms the traditional 3D-QSAR model in rationality, and provides a good example of selecting suitable protein structures for docking prediction and for building structure-based QSAR using available protein structures.

Mesh:

Substances:

Year:  2013        PMID: 24335842      PMCID: PMC4076596          DOI: 10.1038/aps.2013.148

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  42 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  EGFR mutations and sensitivity to gefitinib.

Authors:  Steven M Sorscher
Journal:  N Engl J Med       Date:  2004-09-16       Impact factor: 91.245

3.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

4.  Virtual screening of 4-anilinoquinazoline analogues as EGFR kinase inhibitors: importance of hydrogen bonds in the evaluation of poses and scoring functions.

Authors:  V Aparna; G Rambabu; S K Panigrahi; J A R P Sarma; G R Desiraju
Journal:  J Chem Inf Model       Date:  2005 May-Jun       Impact factor: 4.956

Review 5.  EGF-ERBB signalling: towards the systems level.

Authors:  Ami Citri; Yosef Yarden
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

6.  PHASE: a novel approach to pharmacophore modeling and 3D database searching.

Authors:  Steven L Dixon; Alexander M Smondyrev; Shashidhar N Rao
Journal:  Chem Biol Drug Des       Date:  2006-05       Impact factor: 2.817

7.  Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.

Authors:  A J Barker; K H Gibson; W Grundy; A A Godfrey; J J Barlow; M P Healy; J R Woodburn; S E Ashton; B J Curry; L Scarlett; L Henthorn; L Richards
Journal:  Bioorg Med Chem Lett       Date:  2001-07-23       Impact factor: 2.823

8.  3D-QSAR and receptor modeling of tyrosine kinase inhibitors with flexible atom receptor model (FLARM).

Authors:  Tao Peng; Jianfeng Pei; Jiaju Zhou
Journal:  J Chem Inf Comput Sci       Date:  2003 Jan-Feb

9.  Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2).

Authors:  Allan Wissner; Elsebe Overbeek; Marvin F Reich; M Brawner Floyd; Bernard D Johnson; Nellie Mamuya; Edward C Rosfjord; Carolyn Discafani; Rachel Davis; Xiaoqing Shi; Sridhar K Rabindran; Brian C Gruber; Fei Ye; William A Hallett; Ramaswamy Nilakantan; Ru Shen; Yu-Fen Wang; Lee M Greenberger; Hwei-Ru Tsou
Journal:  J Med Chem       Date:  2003-01-02       Impact factor: 7.446

10.  A comprehensive pathway map of epidermal growth factor receptor signaling.

Authors:  Kanae Oda; Yukiko Matsuoka; Akira Funahashi; Hiroaki Kitano
Journal:  Mol Syst Biol       Date:  2005-05-25       Impact factor: 11.429

View more
  3 in total

1.  Screening of multi-targeted natural compounds for receptor tyrosine kinases inhibitors and biological evaluation on cancer cell lines, in silico and in vitro.

Authors:  Pushpendra Singh; Felix Bast
Journal:  Med Oncol       Date:  2015-08-23       Impact factor: 3.064

2.  Drug design by machine-trained elastic networks: predicting Ser/Thr-protein kinase inhibitors' activities.

Authors:  Cyrus Ahmadi Toussi; Javad Haddadnia; Chérif F Matta
Journal:  Mol Divers       Date:  2020-03-28       Impact factor: 2.943

3.  Synthesis and pharmacological evaluation of novel epidermal growth factor receptor inhibitors against prostate tumor cells.

Authors:  Yi Zhi; Xiaojun Wu; Wenhao Shen; Yongquan Wang; Xiaozhou Zhou; Peng He; Jinhong Pan; Zhiwen Chen; Weibing Li; Zhansong Zhou
Journal:  Oncol Lett       Date:  2018-09-14       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.